Cellcyte Genetics Corp (SHPN) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
PMB189 BELLEVUE, WA 98006 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 9/30/2014 Q3 | 6/30/2014 Q2 | 3/31/2014 Q1 | 12/31/2013 Q4 | 9/30/2013 Q3 | 6/30/2013 Q2 | 3/31/2013 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | (31,859) | ||||||||
| Cash and cash equivalents | (31,859) | ||||||||
| Other undisclosed current assets | 993 | 993 | 9,033 | 17,073 | 56,973 | 2,293 | |||
| Total current assets: | 993 | 993 | 9,033 | 17,073 | 25,114 | 2,293 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 70,002 | ||||||||
| Other undisclosed noncurrent assets | (70,002) | 10,590 | 12,466 | 14,342 | |||||
| Total noncurrent assets: | 10,590 | 12,466 | 14,342 | ||||||
| TOTAL ASSETS: | 993 | 993 | 9,033 | 27,663 | 37,580 | 16,635 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 247,335 | 219,737 | 207,945 | 264,395 | 246,082 | 126,486 | |||
| Accounts payable | 144,389 | 127,249 | 125,540 | 110,997 | 107,148 | ||||
| Accrued liabilities | 102,946 | 92,488 | 82,405 | 153,398 | 138,934 | 126,486 | |||
| Debt | 2,695 | 10,725 | 18,675 | 358,610 | |||||
| Due to related parties | 117,949 | 117,949 | 140,704 | 140,654 | 140,704 | ||||
| Other undisclosed current liabilities | (136,036) | ||||||||
| Total current liabilities: | 365,284 | 337,686 | 351,344 | 415,774 | 405,461 | 349,060 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 515,895 | 477,489 | 385,741 | 371,964 | |||||
| Long-term debt, excluding current maturities | 515,895 | 477,489 | 385,741 | 371,964 | |||||
| Other undisclosed noncurrent liabilities | 524,145 | ||||||||
| Total noncurrent liabilities: | 524,145 | 515,895 | 477,489 | 385,741 | 371,964 | ||||
| Total liabilities: | 889,429 | 853,581 | 828,833 | 801,515 | 777,425 | 349,060 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (888,436) | (852,588) | (819,800) | (773,852) | (739,845) | 11,684,868 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (49,154) | (49,154) | (49,154) | (49,154) | (49,154) | (49,154) | |||
| Additional paid in capital | 11,734,022 | 11,734,022 | 11,734,022 | 11,734,022 | 11,734,022 | 11,734,022 | |||
| Other undisclosed equity, attributable to parent | (12,573,304) | (12,537,456) | (12,504,668) | (12,458,720) | (12,424,713) | ||||
| Total equity: | (888,436) | (852,588) | (819,800) | (773,852) | (739,845) | 11,684,868 | |||
| Other undisclosed liabilities and equity | (12,017,293) | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 993 | 993 | 9,033 | 27,663 | 37,580 | 16,635 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 9/30/2014 Q3 | 6/30/2014 Q2 | 3/31/2014 Q1 | 12/31/2013 Q4 | 9/30/2013 Q3 | 6/30/2013 Q2 | 3/31/2013 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (25,240) | (22,753) | (34,014) | (25,415) | (38,954) | (25,767) | ||
| Other operating expense, net | (10,609) | (10,034) | (11,935) | (8,592) | (9,856) | |||
| Operating loss: | (35,849) | (32,787) | (45,949) | (34,007) | (48,810) | (25,767) | ||
| Loss from continuing operations: | (35,849) | (32,787) | (45,949) | (34,007) | (48,810) | (25,767) | ||
| Loss before gain (loss) on sale of properties: | (35,849) | (32,787) | (45,949) | (34,007) | (48,810) | (25,767) | ||
| Other undisclosed net loss | (9,506) | |||||||
| Net loss available to common stockholders, diluted: | (35,849) | (32,787) | (45,949) | (34,007) | (48,810) | (35,273) | ||
Comprehensive Income (USD)Annual | Quarterly
| 9/30/2014 Q3 | 6/30/2014 Q2 | 3/31/2014 Q1 | 12/31/2013 Q4 | 9/30/2013 Q3 | 6/30/2013 Q2 | 3/31/2013 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (35,849) | (32,787) | (45,949) | (34,007) | (48,810) | (35,273) | ||
| Comprehensive loss, net of tax, attributable to parent: | (35,849) | (32,787) | (45,949) | (34,007) | (48,810) | (35,273) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.